LUNA +12.97% 24H - Terra Network Upgrade Scheduled

Generated by AI AgentCryptoPulse AlertReviewed byAInvest News Editorial Team
Friday, Dec 5, 2025 1:04 am ET1min read
Aime RobotAime Summary

- LUNA surged 12.97% in 24 hours to $0.0811, but remains down 79.77% year-to-date amid market challenges.

- Binance paused LUNA deposits/withdrawals on Dec 8, 2025, for a Terra network upgrade to secure the network during protocol updates.

- Adverum’s LUNA Phase 2 trial showed a 90% reduction in anti-VEGF injections for wet AMD, with sustained efficacy and safety over two years.

- Analysts anticipate increased Terra on-chain activity post-upgrade, though broader crypto volatility persists, urging investors to monitor ecosystem developments and macroeconomic factors.

On DEC 5 2025, LUNA surged by 12.97% within 24 hours to reach $0.0811, marking a continuation of its upward trajectory. Over the past seven days, the cryptocurrency rose by 16.2%, and the one-month gain mirrors this performance. Despite the recent rally, LUNA remains down 79.77% year-to-date, reflecting broader market challenges.

Terra Network Upgrade to Pause LUNA Deposits and Withdrawals

Binance has announced it will suspend LUNA (Terra) token deposits and withdrawals on December 8, 2025, at 20:05 UTC+8, to facilitate a scheduled network upgrade. The maintenance period is expected to last until approximately 21:05 UTC+8 on the same day, aligning with the anticipated block height of 18,660,000. The exchange emphasized that the action is aimed at maintaining network security and ensuring a smooth transition during the protocol update.

Traders are advised to monitor Binance's official communication channels for real-time updates and confirmations following the upgrade. As the network evolves, the move underscores continued development efforts across the

ecosystem.

LUNA Biotech Trial Shows Strong Long-Term Outcomes in Wet AMD Patients

Separately, Adverum Biotechnologies, Inc. released two-year follow-up data from its LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The biotech firm highlighted that Ixo-vec led to a nearly 90% reduction in anti-VEGF injections over the study period, maintaining sustained anatomic control and visual acuity in both tested dose groups. Notably, no new inflammation was observed after week 30 in the 6E10 dose group.

The Phase 3 ARTEMIS trial is expected to be fully enrolled by December 5, 2025, and the therapy continues to demonstrate a favorable safety profile. The findings represent a significant step forward in the development of a durable gene therapy for chronic eye conditions.

Analysts Project Continued Momentum for Terra Ecosystem

Analysts project that the Terra network upgrade may lead to increased on-chain activity, reinforcing the project’s long-term growth strategy. While the short-term price movement appears to be driven by the upgrade news and biotech data, the broader market remains volatile. Investors are advised to evaluate developments within the Terra ecosystem alongside macroeconomic factors affecting the wider crypto market.

As the Terra upgrade proceeds and LUNA’s biotech application advances, the dual narratives of blockchain innovation and medical science may contribute to renewed investor interest in the asset.

Comments



Add a public comment...
No comments

No comments yet